Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Aim: To examine the efficacy of the combination of galantamine and memantine for the
treatment of cognitive deficits in outpatients with schizophrenia.
Hypothesis: A combination of galantamine and memantine will improve cognitive impairments in
patients with schizophrenia.
This is an open-label study to evaluate whether a six week course of galantamine ER and
memantine XR is effective in improving the cognitive performance of patients with
schizophrenia or schizoaffective disorder. The primary outcome measure will be the change in
level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). The results
of the MATRICS collaborative project recommended the need for standardized cognitive tests
that better distinguish the different facets of cognitive dysfunction in schizophrenia. The
MCCB will assess the following seven domains: attention/vigilance, reasoning and problem
solving, processing speed, social cognition, verbal learning and memory, visual learning and
memory, and working memory. The MCCB will be administered at baseline and at the end of the
study. We will report total score and each domain score in the MCCB at baseline and six
weeks.